SEB Asset Management AB Takes Position in Halozyme Therapeutics, Inc. $HALO

SEB Asset Management AB acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 34,700 shares of the biopharmaceutical company’s stock, valued at approximately $2,243,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $128,201,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $124,031,000. Voloridge Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $77,587,000. Qube Research & Technologies Ltd purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $51,295,000. Finally, Mizuho Markets Americas LLC lifted its position in Halozyme Therapeutics by 270.8% in the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock valued at $85,382,000 after buying an additional 926,526 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 3.9%

Shares of HALO opened at $80.84 on Friday. The stock has a market capitalization of $9.59 billion, a PE ratio of 29.08, a P/E/G ratio of 0.32 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 1 year low of $57.67 and a 1 year high of $82.26. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company’s 50-day simple moving average is $72.79 and its 200-day simple moving average is $70.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the firm posted $1.11 earnings per share. The business’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the subject of several research analyst reports. UBS Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. HC Wainwright restated a “buy” rating and issued a $95.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday. Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.60.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. This trade represents a 33.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $55,088,215. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 74,102 shares of company stock valued at $5,205,798 in the last 90 days. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.